UY35427A - Compuestos y sus usos en la modulación de la hemoglobina - Google Patents

Compuestos y sus usos en la modulación de la hemoglobina

Info

Publication number
UY35427A
UY35427A UY0001035427A UY35427A UY35427A UY 35427 A UY35427 A UY 35427A UY 0001035427 A UY0001035427 A UY 0001035427A UY 35427 A UY35427 A UY 35427A UY 35427 A UY35427 A UY 35427A
Authority
UY
Uruguay
Prior art keywords
hemoglobin
compounds
modulation
methods
disorders
Prior art date
Application number
UY0001035427A
Other languages
English (en)
Inventor
Jason R Harris
Brian W Metcalf
Calvin W Yee
Xu Qing
Stephen L Gwaltney
Li Zhe
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/815,874 external-priority patent/US9604999B2/en
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of UY35427A publication Critical patent/UY35427A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

La presente invención proporciona compuestos y composiciones farmacéuticas, adecuadas como moduladores de la hemoglobina, los métodos y productos intermediarios para su preparación, y los métodos para su uso en el tratamiento de trastornos mediados por la hemoglobina y los trastornos que se beneficiarían con la oxigenación de tejidos y/o células.
UY0001035427A 2013-03-15 2014-03-13 Compuestos y sus usos en la modulación de la hemoglobina UY35427A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/815,874 US9604999B2 (en) 2013-03-15 2013-03-15 Compounds and uses thereof for the modulation of hemoglobin
US201361905802P 2013-11-18 2013-11-18

Publications (1)

Publication Number Publication Date
UY35427A true UY35427A (es) 2014-10-31

Family

ID=51580729

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035427A UY35427A (es) 2013-03-15 2014-03-13 Compuestos y sus usos en la modulación de la hemoglobina

Country Status (19)

Country Link
US (3) US11236109B2 (es)
EP (1) EP2968299B1 (es)
JP (2) JP6401771B2 (es)
KR (1) KR20150132146A (es)
CN (1) CN105246477A (es)
AP (1) AP2015008718A0 (es)
AU (1) AU2014237330A1 (es)
BR (1) BR112015021986A2 (es)
CA (1) CA2902711C (es)
EA (1) EA201591426A1 (es)
ES (1) ES2864707T3 (es)
IL (1) IL240839A0 (es)
MX (1) MX2015011769A (es)
PE (1) PE20160078A1 (es)
SG (1) SG11201507453VA (es)
TW (1) TW201446741A (es)
UY (1) UY35427A (es)
WO (1) WO2014150258A1 (es)
ZA (1) ZA201506433B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
PT3738434T (pt) 2011-12-28 2023-11-13 Global Blood Therapeutics Inc Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
PE20160078A1 (es) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
EA033555B1 (ru) 2013-03-15 2019-10-31 Global Blood Therapeutics Inc Фармацевтические композиции для лечения серповидно-клеточного нарушения
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
MY189995A (en) 2014-02-07 2022-03-22 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
EP3472150A1 (en) 2016-06-17 2019-04-24 Fronthera U.S. Pharmaceuticals LLC Hemoglobin modifier compounds and uses thereof
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
MX2021006095A (es) 2018-11-29 2021-07-06 Pfizer Pirazoles como moduladores de hemoglobina.
EP3898618A1 (en) * 2018-12-21 2021-10-27 Crystal Pharma, S.A.U. Process and intermediates for the preparation of voxelotor
WO2023248174A1 (en) * 2022-06-22 2023-12-28 Hetero Labs Limited An improved process for preparation of voxelotor

Family Cites Families (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE226590C (es)
DE276479C (es)
DE258226C (es)
DE1287717B (de) 1956-02-13 1969-01-23 International Polaroid Corp., Jersey City, N.J. (V.St.A.) Verfahren zur Herstellung von Azofarbstoffen
BE787576A (fr) 1971-08-13 1973-02-14 Hoechst Ag Derives de benzofuranne et leur utilisation comme azureurs optiques
BE787580A (fr) 1971-08-13 1973-02-14 Hoechst Ag Procede de preparation de derives du furanne
GB1409865A (en) 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
US4062858A (en) 1976-12-22 1977-12-13 E. R. Squibb & Sons, Inc. Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines
GB1593417A (en) 1976-12-22 1981-07-15 Squibb & Sons Inc Carbocyclic-fused pyrazolopyridine derivatives
EP0010063B1 (de) 1978-10-04 1982-12-29 Ciba-Geigy Ag Verfahren zur Herstellung von Furanyl-benzazolen
DE2853765A1 (de) 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
DE2904829A1 (de) 1979-02-08 1980-08-14 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuran
EP0022229B1 (en) 1979-06-29 1982-12-08 The Wellcome Foundation Limited Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof
DE3175083D1 (en) * 1980-12-18 1986-09-11 Wellcome Found Pharmaceutical compounds, their preparation and use
JPS5929667A (ja) 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体および強心剤
US4478834A (en) 1983-02-11 1984-10-23 Usv Pharmaceutical Corporation Dihydropyridines and their use in the treatment of asthma
GB8402740D0 (en) 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
JPS6140236A (ja) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd ハイドロキノン誘導体
DE3431004A1 (de) 1984-08-23 1986-03-06 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung
GB8603475D0 (en) 1986-02-12 1986-03-19 Glaxo Group Ltd Chemical compounds
DK111387A (da) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPS63258463A (ja) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd ２−フエノキシピリミジン誘導体及び除草剤
GB8711802D0 (en) 1987-05-19 1987-06-24 Fujisawa Pharmaceutical Co Dithioacetal compounds
GB8718940D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
US4920131A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
JP2650038B2 (ja) 1988-01-27 1997-09-03 サントリー株式会社 ピロリチジン化合物およびその用途
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
US4952574A (en) 1988-09-26 1990-08-28 Riker Laboratories, Inc. Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides
IE81170B1 (en) 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IT1230859B (it) 1989-06-05 1991-11-08 Corvi Camillo Spa 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
EP0453210A3 (en) 1990-04-19 1993-01-13 Imperial Chemical Industries Plc Pyridine derivatives
IL98526A0 (en) 1990-06-18 1992-07-15 Merck & Co Inc Pyridones,processes for their preparation and pharmaceutical compositions containing them
WO1991019697A1 (en) 1990-06-19 1991-12-26 Meiji Seika Kabushiki Kaisha Pyridine derivative with angiotensin ii antagonism
NL9001752A (nl) 1990-08-02 1992-03-02 Cedona Pharm Bv Nieuwe 1,4-dihydropyridinederivaten.
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
JPH05301872A (ja) 1992-04-23 1993-11-16 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
US5403816A (en) 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
EP0498380A1 (de) 1991-02-08 1992-08-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Komplexbildner
JPH0641118A (ja) 1991-05-31 1994-02-15 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
US5185251A (en) 1991-06-07 1993-02-09 Merck & Co., Inc. Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5202243A (en) 1991-10-04 1993-04-13 Merck & Co., Inc. Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices
GB9203798D0 (en) 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
EP0648209A1 (de) 1992-07-01 1995-04-19 Byk Gulden Lomberg Chemische Fabrik GmbH Kontrastmittel für die mr diagnostik
US5290941A (en) 1992-10-14 1994-03-01 Merck & Co., Inc. Facile condensation of methylbenzoxazoles with aromatic aldehydes
CA2135474C (en) 1993-04-07 1998-11-10 Shingo Yano Thiazolidine derivatives and pharmaceutical compositions containing the same
DE4318550A1 (de) 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU672699B2 (en) 1993-06-30 1996-10-10 Sankyo Company Limited Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
JPH0725882A (ja) 1993-07-07 1995-01-27 Res Dev Corp Of Japan アクロメリン酸ｂおよびｅを製造するための中間体と、その製造方法
DK0637586T3 (da) 1993-08-05 1999-12-06 Hoechst Marion Roussel Inc 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse
EP0640609A1 (en) 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
WO1995014015A1 (en) 1993-11-19 1995-05-26 Ciba-Geigy Ag Benzothiophene derivatives possessing a methoxyimino substituent as microbicides
EP0658559A1 (de) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
PT750631E (pt) 1994-02-14 2000-07-31 Merrell Pharma Inc Novos derivados de dissulfureto de mercapto-aacetilamido-1,3,4,5-tetra-hidro-benzo¬c)azepin-3-ona uteis como inibidores de encefalinase e ace
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
DE4442050A1 (de) 1994-11-25 1996-05-30 Hoechst Ag Heterospiroverbindungen und ihre Verwendung als Elektrolumineszenzmaterialien
US5650408A (en) 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
JP3895404B2 (ja) 1996-05-17 2007-03-22 興和株式会社 カルコン誘導体及びこれを含有する医薬
EP0923580A1 (en) 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
AU717430B2 (en) 1996-08-26 2000-03-23 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
AU4136197A (en) 1996-09-09 1998-03-26 Kyowa Hakko Kogyo Co. Ltd. Pyrrolocarbazole derivatives
WO1998021199A2 (en) 1996-11-12 1998-05-22 Novartis Ag Pyrazole derivatives useful as herbicides
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5760232A (en) 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
BR9815170A (pt) 1997-12-12 2000-10-10 Euro Celtique S A Luxembourg "método de obter composto aplicável no tratamento de asma em mamìferos"
CN1298404A (zh) 1998-02-25 2001-06-06 遗传研究所有限公司 磷脂酶a2的抑制剂
CA2319493A1 (en) 1998-03-18 1999-09-23 Regine Bohacek Heterocyclic signal transduction inhibitors, compositions containing them
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9810860D0 (en) 1998-05-20 1998-07-22 Hoechst Schering Agrevo Gmbh Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides
SK18542000A3 (sk) 1998-06-04 2001-12-03 Abbott Laboratories Protizápalové zlúčeniny inhibujúce bunkovú adhéziu
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
KR100473966B1 (ko) 1998-12-14 2005-03-08 에프. 호프만-라 로슈 아게 페닐글리신 유도체
WO2000040564A1 (en) 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
US6544980B2 (en) 1998-12-31 2003-04-08 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
US6472349B1 (en) 1999-03-31 2002-10-29 Basf Aktiengesellschaft Pyridine-2,3-dicarboxylic acid diamides
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
JP2002544242A (ja) 1999-05-14 2002-12-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 酵素活性化抗腫瘍プロドラッグ化合物
US6184228B1 (en) 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
ATE258928T1 (de) 1999-06-28 2004-02-15 Janssen Pharmaceutica Nv Respiratorisches syncytialvirus replikation inhibitoren
IL148631A0 (en) 1999-09-28 2002-09-12 Eisai Co Ltd Quinuclidine derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
KR100788970B1 (ko) 1999-11-05 2007-12-27 에미스페어 테크놀로지스, 인코포레이티드 활성제 전달용 페녹시 카르복시산 화합물 및 조성물
AUPQ407699A0 (en) 1999-11-16 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
WO2001051919A2 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
AU2001230537A1 (en) 2000-02-01 2001-08-14 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
US6506755B2 (en) 2000-02-03 2003-01-14 Hoffmann-La Roche Inc. Thiazolidinecarboxyl acids
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
WO2001070663A2 (en) 2000-03-17 2001-09-27 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
CZ303639B6 (cs) 2000-07-14 2013-01-23 F. Hoffmann-La Roche Ag N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem
AU2001281071A1 (en) 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6653313B2 (en) 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
NZ525700A (en) 2000-11-20 2004-12-24 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
WO2002051849A1 (fr) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs cdk4
CA2433573A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Alkanoic acid derivatives, process for their production and use thereof
US20030022923A1 (en) 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US20030073712A1 (en) 2001-07-23 2003-04-17 Bing Wang Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
JP2003075970A (ja) 2001-08-31 2003-03-12 Konica Corp ハロゲン化銀カラー写真感光材料、カラー写真感光材料、その画像形成方法及びデジタル画像情報作製方法
KR100467313B1 (ko) 2001-11-22 2005-01-24 한국전자통신연구원 적색 유기 전기발광 화합물 및 그 제조 방법과 전기발광소자
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CN1596240A (zh) 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
US20030190333A1 (en) 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
AU2003230985A1 (en) 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
CA2493908A1 (en) 2002-08-08 2004-02-19 Smithkline Beecham Corporation Thiophene compounds
AU2003257666A1 (en) 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
AU2003262023A1 (en) 2002-09-10 2004-04-30 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
ES2372047T3 (es) 2002-12-04 2012-01-13 Virginia Commonwealth University Agentes antidrepanocíticos.
AU2003303239A1 (en) 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
AU2003289440A1 (en) 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
DE50303264D1 (de) 2003-02-24 2006-06-08 Randolph Riemschneider Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung
US20040186077A1 (en) 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
RU2337908C2 (ru) 2003-06-12 2008-11-10 Ново Нордиск А/С Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
KR20080042188A (ko) 2003-11-05 2008-05-14 에프. 호프만-라 로슈 아게 Ｐｐａｒ 작용제로서 페닐 유도체
US20050101644A1 (en) 2003-11-10 2005-05-12 Schering Aktiengesellschaft Benzylether amine compounds useful as CCR-5 antagonists
EP1694328A4 (en) 2003-12-02 2010-02-17 Celgene Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA
US7378439B2 (en) 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
CN101014571A (zh) 2004-01-30 2007-08-08 默克公司 用作hiv整合酶抑制剂的n－苄基－3,4－二羟基吡啶－2－羧酰胺类和n－苄基－2,3－二羟基吡啶－4－羧酰胺类化合物
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
EP1725554A1 (en) 2004-03-09 2006-11-29 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
US20080132458A1 (en) 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
DE102004015226B3 (de) 2004-03-24 2005-08-25 Siemens Ag Verfahren zum Plasmareinigen eines Werkstücks und zu dessen Durchführung geeignete Vorrichtung
WO2005102305A2 (en) * 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Compositions of allosteric hemoglobin modifiers and methods of making the same
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005304220A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20080287399A1 (en) 2004-12-14 2008-11-20 Astrazeneca Ab Substituted Aminopyridines and Uses Thereof
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
EP1861357B1 (en) 2005-03-19 2013-04-24 Amorepacific Corporation Novel compounds or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd A PYRIDINE DERIVATIVE ANTIPILIC AGENT
GB0506677D0 (en) 2005-04-01 2005-05-11 Btg Int Ltd Iron modulators
ES2437268T3 (es) 2005-04-28 2014-01-09 Viiv Healthcare Company Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH
DE102005025989A1 (de) 2005-06-07 2007-01-11 Bayer Cropscience Ag Carboxamide
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
CN100562514C (zh) 2005-07-22 2009-11-25 中国科学院上海药物研究所 一类取代丙酰胺衍生物、其制备方法和用途
GB0516270D0 (en) 2005-08-08 2005-09-14 Glaxo Group Ltd Novel compounds
JP5557449B2 (ja) 2005-10-11 2014-07-23 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾフラン化合物
CA2626956A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
EP1948614A2 (en) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
EP1976851A2 (en) 2006-01-17 2008-10-08 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists
WO2007095495A2 (en) 2006-02-13 2007-08-23 Pharmacopeia, Inc. Benzodiazepine gcnf modulators for stem cell modulation
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
GB0614586D0 (en) 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
CN101113148A (zh) 2006-07-26 2008-01-30 中国海洋大学 二氧哌嗪类化合物及其制备方法和用途
AU2007277519B2 (en) 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
CN101506143B (zh) 2006-09-03 2013-06-05 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的对乙酰氨基酚及其相关化合物的前药
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
MX2009004385A (es) 2006-10-23 2009-05-22 Merck & Co Inc Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide.
TW200835687A (en) 2006-11-30 2008-09-01 R Tech Ueno Ltd Thiazole derivatives and their use as VAP-1 inhibitor
WO2008066151A1 (en) 2006-11-30 2008-06-05 Tokyo Institute Of Technology Novel curcumin derivative
FR2909379B1 (fr) 2006-11-30 2009-01-16 Servier Lab Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US8513286B2 (en) 2007-02-22 2013-08-20 Syngenta Crop Protection Llc Iminipyridine derivatives and their uses as microbiocides
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
EP2149545B1 (en) 2007-05-22 2016-10-05 Sumitomo Chemical Company, Limited Method for producing benzaldehyde compound
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
RU2440989C2 (ru) * 2007-07-17 2012-01-27 Ф.Хоффманн-Ля Рош Аг ИНГИБИТОРЫ 11β-ГИДРОКСИСТЕРОИДНОЙ ДЕГИДРОГЕНАЗЫ
AU2008280135B2 (en) 2007-07-26 2012-02-23 Novartis Ag Organic compounds
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
CA2703037A1 (en) 2007-10-17 2009-04-23 Novartis Ag Organic compounds
PL2227467T3 (pl) 2007-12-04 2015-05-29 Hoffmann La Roche Pochodne izoksazolo-pirydyny
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
JP2009203230A (ja) 2008-01-31 2009-09-10 Daiichi Sankyo Co Ltd ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物
DK2241546T3 (da) 2008-02-14 2017-11-13 Sumitomo Chemical Co Fremgangsmåde til fremstilling af en benzaldehydforbindelse
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
RU2010145916A (ru) 2008-04-11 2012-05-20 Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp) Ингибитор pai-1
JP2011136906A (ja) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
ES2599002T3 (es) 2008-05-08 2017-01-31 Nova Southeastern University Inhibidores específicos para receptores del factor de crecimiento endotelial vascular
WO2009146555A1 (en) 2008-06-04 2009-12-10 Ambrilia Biopharma Inc. Hiv integrase inhibitors from pyridoxine
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
JP5314330B2 (ja) 2008-06-16 2013-10-16 住友化学株式会社 ２−（アリールオキシメチル）ベンズアルデヒドの製造方法およびその中間体
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
US8815875B2 (en) 2008-11-12 2014-08-26 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
PL2732818T3 (pl) 2009-03-31 2017-12-29 Ligand Pharmaceuticals Inc. Bifenylosulfonamidowy antagonista receptora endoteliny i angiotensyny II do leczenia stwardnienia kłębków nerkowych
US8367654B2 (en) 2009-05-08 2013-02-05 Tetraphase Pharmaceuticals, Inc. 8-AZA tetracycline compounds
WO2011024869A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
EP2474540A4 (en) 2009-08-31 2013-03-13 Nippon Chemiphar Co GPR119 AGONIST
AU2010297290A1 (en) 2009-09-21 2012-03-15 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
RS59599B2 (sr) 2009-11-09 2023-03-31 Wyeth Llc Formulacije tableta neratinib maleata
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
KR101698153B1 (ko) 2010-04-26 2017-01-23 광주과학기술원 Ｐ2ｘ1 및 ｐ2ｘ3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물
CN102232949A (zh) 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
TWI535442B (zh) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
CN102116772B (zh) 2010-09-28 2013-08-28 上海大学 二氢查尔酮化合物的筛选方法
AU2011350396A1 (en) 2010-12-27 2013-07-11 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
EP2694514A2 (en) * 2011-04-06 2014-02-12 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
RU2625790C2 (ru) 2011-04-11 2017-07-19 Грин Тек Ко.,Лтд. Новое пиразольное производное
MX2014001933A (es) 2011-09-15 2014-03-27 Demerx Inc Ansolvatos de sal de noribogaina.
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
PT3738434T (pt) * 2011-12-28 2023-11-13 Global Blood Therapeutics Inc Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
BR112015015216B1 (pt) 2012-12-27 2020-01-07 Sumitomo Chemical Company, Limited Composto de tetrazolinona, agente e método de controle de peste
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20160078A1 (es) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA033555B1 (ru) 2013-03-15 2019-10-31 Global Blood Therapeutics Inc Фармацевтические композиции для лечения серповидно-клеточного нарушения
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2902709A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2970184B1 (en) 2013-03-15 2018-12-05 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105209469A (zh) 2013-03-15 2015-12-30 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20160206604A1 (en) 2013-08-26 2016-07-21 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
WO2015031285A1 (en) 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
WO2015116061A1 (en) 2014-01-29 2015-08-06 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
MY189995A (en) 2014-02-07 2022-03-22 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
TWI544395B (zh) 2014-09-26 2016-08-01 義隆電子股份有限公司 單層電容式觸控面板之掃描方法及裝置
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
DK3880654T3 (da) 2018-11-19 2022-03-07 Global Blood Therapeutics Inc 2-formyl-3-hydroxyphenyloxymethylforbindelse som er i stand til at modulere hæmoglobin

Also Published As

Publication number Publication date
MX2015011769A (es) 2016-06-02
JP6401771B2 (ja) 2018-10-10
EP2968299B1 (en) 2021-01-20
AP2015008718A0 (en) 2015-09-30
IL240839A0 (en) 2015-10-29
PE20160078A1 (es) 2016-03-02
US20220402940A1 (en) 2022-12-22
JP2016512822A (ja) 2016-05-09
JP2018188482A (ja) 2018-11-29
EA201591426A1 (ru) 2016-02-29
ZA201506433B (en) 2019-09-25
EP2968299A1 (en) 2016-01-20
BR112015021986A2 (pt) 2017-07-18
CA2902711C (en) 2021-07-06
ES2864707T3 (es) 2021-10-14
AU2014237330A1 (en) 2015-09-17
US11236109B2 (en) 2022-02-01
EP2968299A4 (en) 2016-08-24
CA2902711A1 (en) 2014-09-25
KR20150132146A (ko) 2015-11-25
US20220119407A1 (en) 2022-04-21
TW201446741A (zh) 2014-12-16
SG11201507453VA (en) 2015-10-29
WO2014150258A1 (en) 2014-09-25
US20200048280A1 (en) 2020-02-13
CN105246477A (zh) 2016-01-13

Similar Documents

Publication Publication Date Title
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
CR20150316A (es) Compuestos y sus métodos de empleo
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
GT201400164A (es) Compuestos de imidazopirrolidinona
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
CR20150524A (es) Compuestos de heteroarilo y sus usos
CR20150571A (es) Compuestos y composiciones terapéuticos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
UY34773A (es) Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
CO7350653A2 (es) Retinoides y uso de los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211112